SG11201501740XA - Therapeutic agent for dyslipidemia - Google Patents

Therapeutic agent for dyslipidemia

Info

Publication number
SG11201501740XA
SG11201501740XA SG11201501740XA SG11201501740XA SG11201501740XA SG 11201501740X A SG11201501740X A SG 11201501740XA SG 11201501740X A SG11201501740X A SG 11201501740XA SG 11201501740X A SG11201501740X A SG 11201501740XA SG 11201501740X A SG11201501740X A SG 11201501740XA
Authority
SG
Singapore
Prior art keywords
dyslipidemia
therapeutic agent
therapeutic
agent
Prior art date
Application number
SG11201501740XA
Other languages
English (en)
Inventor
Toshiaki Takizawa
Yasunobu Yoshinaka
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of SG11201501740XA publication Critical patent/SG11201501740XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201501740XA 2012-09-27 2013-09-27 Therapeutic agent for dyslipidemia SG11201501740XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012214635 2012-09-27
PCT/JP2013/005756 WO2014050134A1 (ja) 2012-09-27 2013-09-27 脂質異常症治療剤

Publications (1)

Publication Number Publication Date
SG11201501740XA true SG11201501740XA (en) 2015-04-29

Family

ID=50387566

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201501740XA SG11201501740XA (en) 2012-09-27 2013-09-27 Therapeutic agent for dyslipidemia

Country Status (21)

Country Link
US (4) US9572798B2 (ja)
EP (1) EP2902025B1 (ja)
JP (1) JP6238460B2 (ja)
KR (1) KR102098032B1 (ja)
CN (1) CN104640544B (ja)
AU (1) AU2013321918B2 (ja)
BR (1) BR112015006305B1 (ja)
CA (1) CA2901650C (ja)
EA (1) EA024873B1 (ja)
ES (1) ES2752039T3 (ja)
HK (1) HK1206620A1 (ja)
IL (1) IL237981B (ja)
IN (1) IN2015DN02966A (ja)
MX (1) MX357446B (ja)
MY (1) MY177686A (ja)
PH (1) PH12015500471A1 (ja)
PL (1) PL2902025T3 (ja)
PT (1) PT2902025T (ja)
SG (1) SG11201501740XA (ja)
TW (1) TWI598098B (ja)
WO (1) WO2014050134A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI691331B (zh) * 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
US20200121648A1 (en) * 2017-06-30 2020-04-23 Kowa Company, Ltd. Pharmaceutical composition
US11419854B2 (en) 2017-06-30 2022-08-23 Kowa Company, Ltd. Medicament containing pemafibrate
EP3646863B1 (en) * 2017-06-30 2024-01-03 Kowa Company, Ltd. Pharmaceutical composition
WO2019004447A1 (ja) * 2017-06-30 2019-01-03 興和株式会社 医薬組成物
WO2019004451A1 (ja) * 2017-06-30 2019-01-03 興和株式会社 医薬組成物
EP3646866A4 (en) * 2017-06-30 2021-03-24 Kowa Company, Ltd. PHARMACEUTICAL PREPARATION
JPWO2019004452A1 (ja) * 2017-06-30 2020-04-30 興和株式会社 医薬組成物
EP3646867A4 (en) * 2017-06-30 2021-03-24 Kowa Company, Ltd. PHARMACEUTICAL COMPOSITION
US11446282B2 (en) 2017-12-21 2022-09-20 Kowa Company, Ltd. Methods of treating mixed dyslipidemia and hypertriglycertdemia
CN111741753A (zh) * 2017-12-21 2020-10-02 兴和株式会社 治疗高甘油三酯血症的方法
JP7071538B2 (ja) * 2018-12-27 2022-05-19 興和株式会社 医薬組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ309209B6 (cs) 2001-01-26 2022-05-25 Schering Corporation Farmaceutický prostředek
AU2002347985A1 (en) 2001-11-15 2003-06-10 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
WO2005009942A1 (ja) 2003-07-28 2005-02-03 Kyorin Pharmaceutical Co., Ltd. 光学活性置換フェニルプロピオン酸誘導体
AU2004270538C1 (en) 2003-09-03 2010-01-14 Kowa Co., Ltd PPAR-activating compound and pharmaceutical composition containing same
ZA200601272B (en) * 2003-09-03 2007-04-25 Kowa Co PPAR-activating compound and pharmaceutical composition containing same
DE102004016845A1 (de) 2004-04-07 2005-10-27 Bayer Healthcare Ag Phenylthioessigsäure-Derivate und ihre Verwendung
ATE488236T1 (de) 2004-09-16 2010-12-15 Merck Sharp & Dohme Verbindungen zur behandlung von dyslipidämie und anderer lipidstörungen
TWI359810B (en) 2004-11-04 2012-03-11 Mitsubishi Tanabe Pharma Corp Carboxylic acid derivative containing thiazole rin
WO2007008529A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc Celullar cholesterol absorption modifiers
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
US7884080B2 (en) 2006-09-15 2011-02-08 Schering Plough Corporation Azetidinone derivatives and methods of use thereof
WO2008104875A1 (en) 2007-03-01 2008-09-04 Pfizer Products Inc. Oxazolidinones as cholesterol absorption inhibitors
TWI407955B (zh) 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及/或治療劑
WO2009047240A1 (en) 2007-10-09 2009-04-16 Smithkline Beecham Corporation Indole derivatives useful as ppar activators
DE102007061757A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung

Also Published As

Publication number Publication date
CN104640544A (zh) 2015-05-20
JP6238460B2 (ja) 2017-11-29
KR102098032B1 (ko) 2020-04-07
BR112015006305A2 (pt) 2017-07-04
PT2902025T (pt) 2019-11-04
MX357446B (es) 2018-07-10
US10258609B2 (en) 2019-04-16
CA2901650A1 (en) 2014-04-03
US9572798B2 (en) 2017-02-21
MY177686A (en) 2020-09-23
BR112015006305B1 (pt) 2020-11-17
IN2015DN02966A (ja) 2015-09-18
EP2902025A1 (en) 2015-08-05
US20150196538A1 (en) 2015-07-16
AU2013321918B2 (en) 2018-05-10
TWI598098B (zh) 2017-09-11
KR20150063035A (ko) 2015-06-08
EP2902025B1 (en) 2019-08-07
IL237981A0 (en) 2015-05-31
US9931321B2 (en) 2018-04-03
US20170112811A1 (en) 2017-04-27
CA2901650C (en) 2021-05-04
EA201590653A1 (ru) 2015-07-30
PH12015500471B1 (en) 2015-04-20
US11013722B2 (en) 2021-05-25
EP2902025A4 (en) 2016-03-02
JPWO2014050134A1 (ja) 2016-08-22
EA024873B1 (ru) 2016-10-31
PL2902025T3 (pl) 2020-03-31
AU2013321918A1 (en) 2015-04-23
MX2015003705A (es) 2015-06-10
HK1206620A1 (en) 2016-01-15
IL237981B (en) 2020-05-31
TW201417811A (zh) 2014-05-16
CN104640544B (zh) 2017-05-03
US20180185337A1 (en) 2018-07-05
US20190167645A1 (en) 2019-06-06
ES2752039T3 (es) 2020-04-02
PH12015500471A1 (en) 2015-04-20
WO2014050134A1 (ja) 2014-04-03

Similar Documents

Publication Publication Date Title
HK1203963A1 (en) Novel therapeutic agents
GB201212513D0 (en) Therapeutic agents
HK1206620A1 (en) Therapeutic agent for dyslipidemia
EP2823830A4 (en) MESH-HIGHNESS MEDIUM
EP2867209A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USES
GB201217439D0 (en) Combination therapy
GB201217704D0 (en) Therapeutic agents
PL2723344T3 (pl) Złożony środek leczniczy zawierający monoterpen
HK1219224A1 (zh) 角結膜病症的治療劑
EP2821073A4 (en) CIRCADIAN RHYTHM IMPROVEMENT AGENT
GB201207305D0 (en) Therapy
GB201420971D0 (en) Therapeutic composition
HK1210426A1 (en) Combination therapy
EP2914267A4 (en) TREATMENT OF DARM CONSTIPATION
HK1219662A1 (zh) 血脂異常症治療劑
EP2804853A4 (en) THERAPEUTIC USES
IL236873A0 (en) therapeutic compounds
ZA201405764B (en) Novel therapeutic agents
GB201223021D0 (en) Therapeutic agents
GB201214985D0 (en) Modified therapeutic agents
GB201213712D0 (en) Modified therapeutic agents
GB201212512D0 (en) Therapeutic agents
GB201210233D0 (en) Therapeutic agents
GB201213192D0 (en) Support for therapeutic
GB201211528D0 (en) Therapeutic apparatus